DGAP-News
Biotest AG: Biotest treats first COVID-19 patient with trimodulin - Seite 2
The similarity of the COVID-19 symptoms to the patients treated in the CIGMA trial, justifies the hypothesis that trimodulin has a considerable potential in the treatment of SARS-CoV-2 induced pneumonia.
"We are very pleased, to be able to support physicians with trimodulin for the treatment of patients with severe COVID-19. We hope, that trimodulin will be able to prevent progression of disease and improve patient outcome. As this would also reduce to need for invasive mechanical ventilation, it could alleviate possible capacity limitations within intensive care units", said Daniela Zipp, responsible Head of Clinical Operations at Biotest.
About COVID-19
COVID-19 is a respiratory disease caused by the novel severe acute respiratory syndrome corona virus 2 variant (SARS-CoV-2). While most cases are mild or asymptomatic, COVID-19 patients may present
at the hospital with typical signs of pneumonia requiring oxygen support. This disease stage is regularly accompanied by an excessive immune response and can lead to systemic inflammation
reactions. Furthermore, patients may progress to critical disease with need for intensive care, including invasive mechanical ventilation. This clinical picture and course of the disease resembles
that of sCAP caused by other pathogens.
Lesen Sie auch
About trimodulin (IgM Concentrate)
Biotest' development product trimodulin is an innovative immunoglobulin preparation, purified from human blood plasma. In comparison to standard IgG preparations (IVIG), trimodulin contains
relevant amounts of IgM and IgA in addition to IgG. Trimodulin is currently in clinical development for the treatment of patients with severe community-acquired pneumonia (sCAP) and for patients
with severe COVID-19. Research so far has shown that trimodulin could interfere with a number of mechanisms involved in pathological processes that would otherwise lead to respiratory failure,
sepsis, multi-organ failure and finally to death of the patient. Due to the large variety of polyvalent antibodies present in trimodulin, the impaired immune system is supported in various ways.
The antibodies bind to various types of pathogens including viruses and bacteria as well as their toxins and support their clearance by the immune system. Particularly the IgM component in
trimodulin can reduce dysregulated immune responses, preventing the immune system to attack host tissues, in this case, the lung. In this way, trimodulin may prevent progression of disease,
including the need for invasive mechanical ventilation and other intensive care procedures.